“天价抗癌疗法”CAR-T或将在今年商保价格协商中实现突破

Core Viewpoint - The negotiation for the pricing of CAR-T drugs, including Huyuan Biotech's Nakialunase injection, has shown promising results, indicating a potential breakthrough in the commercial insurance innovative drug directory for 2025 [1] Group 1 - Huyuan Biotech's Nakialunase injection was approved for market launch in 2023, and it represents one of five CAR-T drugs that have passed the review for the commercial insurance innovative drug directory this year [1] - CAR-T therapies have been unable to enter the national medical insurance negotiation process for the past four years due to their high costs [1]